Drug · CHEMBL19019

NALTREXONE

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. NALTREXONE. Drugs and targets, record CHEMBL19019. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL19019

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: NALTREXONE; ChEMBL
ChEMBL ID: CHEMBL19019; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Celupan, Trexal, Vivitrol; ChEMBL
Other names: EN-1639A FREE BASE, EN-1639A [AS HYDROCHLORIDE], NSC-758439, Naltrexona; ChEMBL
Other form: NALTREXONE HYDROCHLORIDE, CHEMBL1201149; Drugs and targets
DrugBank: DB00704; DrugBank
InChIKey: DQCKKXVULJGBQN-XFWGSAIBSA-N; ChEMBL
Open Targets' highest stage: Approval, for 3 of its 83 diseases, from ATC, DailyMed, EMA Human Drugs and TTD; Open Targets

Targets3

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
OPRD1	Opioid receptors; mu/kappa/delta	Opioid receptors; mu/kappa/delta antagonist	ANTAGONIST	https://conductscience.org/library/genes/4985
OPRK1	Opioid receptors; mu/kappa/delta	Opioid receptors; mu/kappa/delta antagonist	ANTAGONIST	https://conductscience.org/library/genes/4986
OPRM1	Opioid receptors; mu/kappa/delta	Opioid receptors; mu/kappa/delta antagonist	ANTAGONIST	https://conductscience.org/library/genes/4988

Source ChEMBL

Diseases83

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
alcohol dependence	Approval	ATC, DailyMed and TTD	82	77	https://conductscience.org/library/drugs?q=MONDO_0007079
opiate dependence	Phase 3	ClinicalTrials.gov	38	38	https://conductscience.org/library/drugs?q=MONDO_0005530
obesity disorder	Approval	EMA Human Drugs	31	29	https://conductscience.org/library/drugs?q=MONDO_0011122
opioid use disorder	Phase 3	ClinicalTrials.gov	21	21	https://conductscience.org/library/drugs?q=EFO_0010702
cocaine dependence	Phase 3	ClinicalTrials.gov	11	11	https://conductscience.org/library/drugs?q=MONDO_0005186
HIV infectious disease	Phase 3	ClinicalTrials.gov	9	9	https://conductscience.org/library/drugs?q=MONDO_0005109
smoking cessation	Phase 2	ClinicalTrials.gov	7	7	https://conductscience.org/library/drugs?q=EFO_0004319
methamphetamine dependence	Phase 3	ClinicalTrials.gov	6	6	https://conductscience.org/library/drugs?q=MONDO_0005419
nicotine dependence	Phase 3	ClinicalTrials.gov	6	6	https://conductscience.org/library/drugs?q=MONDO_0008575
binge eating disorder	Phase 2/3	ClinicalTrials.gov	5	5	https://conductscience.org/library/drugs?q=MONDO_0005582

1 to 10 of 83Source Open Targets

See all 83 diseases

Trials423

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT01601704	Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)	Phase 3	8,910	2017-02-27	naltrexone	Its name	ClinicalTrials.gov
NCT00532779	A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects	Phase 3	1,742	2014-11-21	naltrexone	Its name	ClinicalTrials.gov
NCT00567255	A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects	Phase 3	1,496	2014-11-21	naltrexone	Its name	ClinicalTrials.gov
NCT00456521	A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program	Phase 3	793	2014-11-21	naltrexone	Its name	ClinicalTrials.gov
NCT01218958	ALK21-003: Study of Medisorb® Naltrexone (VIVITROL®) in Alcohol-Dependent Adults	Phase 3	624	2010-12-07	naltrexone	Its name	ClinicalTrials.gov
NCT02032433	Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment	Phase 4	570	2018-01-19	naltrexone	Its name	ClinicalTrials.gov
NCT00474630	A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes	Phase 3	505	2014-11-21	naltrexone	Its name	ClinicalTrials.gov
NCT05579249	A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America	Phase 4	500	2026-01-14	naltrexone	Its name	ClinicalTrials.gov
NCT01218997	ALK21-006: Long-Term Study of Medisorb® Naltrexone (VIVITROL®)	Phase 3	436	2010-12-13	naltrexone	Its name	ClinicalTrials.gov
NCT03078075	Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder	Phase 3	403	2021-03-29	naltrexone	Its name	ClinicalTrials.gov

1 to 10 of 423

See all 423 trials

Comparisons in its trials243

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
NB32 vs Placebo: Percentage of Participants With a Confirmed Occurrence of Myocardial Infarction (Nonfatal or Fatal)	55 of 4,455	57 of 4,450	8,905	NCT01601704	Trial comparisons
NB32 vs Placebo: Percentage of Participants With a Confirmed Occurrence of Cardiovascular Death (Including Fatal Myocardial Infarction, Fatal Stroke)	17 of 4,455	34 of 4,450	8,905	NCT01601704	Trial comparisons
NB32 vs Placebo: Percentage of Participants With a Confirmed Occurrence of Major Adverse Cardiovascular Event (MACE)	90 of 4,455	102 of 4,450	8,905	NCT01601704	Trial comparisons
NB32 vs Placebo: Percentage of Participants With a Confirmed Occurrence of Stroke (Nonfatal or Fatal)	22 of 4,455	21 of 4,450	8,905	NCT01601704	Trial comparisons
NB32 vs Placebo: Percentage of Participants With a Confirmed Occurrence of Cardiovascular Death, Nonfatal Myocardial Infarction, Nonfatal Stroke, or Nonfatal Unstable Angina Requiring Hospitalization	133 of 4,455	142 of 4,450	8,905	NCT01601704	Trial comparisons
NB32 vs Placebo: serious adverse events	463 of 4,455	386 of 4,450	8,905	NCT01601704	Trial comparisons
NB32/48 vs Placebo: serious adverse events	21 of 992	7 of 492	1,484	NCT00567255	Trial comparisons
NB32 vs Placebo: serious adverse events	22 of 584	1 of 200	784	NCT00456521	Trial comparisons
Extended-Release Naltrexone vs Buprenorphine-Naloxone: Other Drug Use Over Time, Stimulant, W24	5 of 283	3 of 287	570	NCT02032433	Trial comparisons
Extended-Release Naltrexone vs Buprenorphine-Naloxone: Other Drug Use Over Time, Cannabis, W24	20 of 283	20 of 287	570	NCT02032433	Trial comparisons

1 to 10 of 243

See all 243 comparisons in its trials

Papers from its trials270

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
34033183	RESULT	1	PubMed
34013473	RESULT	1	PubMed
33997645	RESULT	1	PubMed
33497547	RESULT	1	PubMed
32629197	RESULT	1	PubMed
32446635	RESULT	1	PubMed
30937241	RESULT	1	PubMed
29674251	RESULT	1	PubMed
29310498	RESULT	2	PubMed
29255898	RESULT	1	PubMed

1 to 10 of 270

See all 270 papers from its trials

Tests in its trials17

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

Test	Trials naming it as an outcome	As a primary outcome	Source
Delay Discounting	3	2	ConductCognition
Food Cue Reactivity Task	3	1	ConductCognition
Dot-Probe Task	2	2	ConductCognition
Simple Reaction Time	2	1	ConductCognition
Stroop Color-Word Test	2	0	ConductCognition
Continuous Performance Test	1	0	ConductCognition
Choice Reaction Time	1	1	ConductCognition
Effort for Rewards Task	1	1	ConductCognition
Go/No-Go Task	1	1	ConductCognition
Monetary Incentive Delay	1	1	ConductCognition

1 to 10 of 17

See all 17 tests in its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL19019

GET https://conductscience.org/api/drugs/v1/CHEMBL19019/diseases?page=2

API reference For AI assistants